The subcu portion of the anti-CD20 market is substantial and being able to compete in this space, we believe, could nearly double our total addressable market opportunity. Beyond MS, we are actively advancing plans to explore BRIUMVI in additional autoimmune indications, including having treated a series of Myasthenia Gravis patients in a Phase I study. And finally, Azer-cel, our allogeneic anti-CD19 CAR-T is being studied in patients with progressive MS. It's still early, but momentum is building. Our clin ...

Delivered $616 million in total global revenue for 2025, driven by $594 million in U.S. BRIUMVI net sales, representing 92% year-over-year growth. Performance was characterized by consistent increases in new patient starts and a broadening prescriber base across both academic and community settings. Management attributes sustained momentum to physician confidence in long-term data, specifically 6-year extension results showing 90% of patients remained disability-progression free. The company achieve ...

Core Viewpoint - TG Therapeutics Inc. is recognized as one of the best revenue growth stocks to consider for investment, with analysts maintaining positive ratings despite some adjustments in price targets [1][3]. Group 1: Analyst Ratings and Price Targets - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while keeping an Overweight rating on the shares [1]. - H.C. Wainwright analyst Emily Bodnar assigned a Buy rating, highlighting the company's strong commercial momentum and expected clinical catalysts in 2026 [3]. - TD Cowen analyst Tara Bancroft reiterated a Buy rating and set a price target of $50 for TG Therapeutics [3]. Group 2: Clinical Developments - TG Therapeutics presented trial results for its Briumvi treatment for relapsing multiple sclerosis at a medical forum in San Diego on February 6 [3]. - The anticipated clinical catalysts include results for consolidated IV dosing and a self-administered subcutaneous formulation for Briumvi, which could enhance its market share against competitors [3].

Economic Indicators - US November retail sales increased by +0.6% month-over-month, surpassing expectations of +0.5% [1] - US November PPI final demand rose by +3.0% year-over-year, exceeding expectations of +2.7% [1] - US December existing home sales rose by +5.1% month-over-month to a 2.75-year high of 4.35 million, stronger than the expected 4.22 million [4] Stock Market Performance - The S&P 500 Index decreased by -0.96%, the Dow Jones Industrials Index fell by -0.57%, and the Nasdaq 100 Index dropped by -1.53% [4] - Weakness in chip makers and the Magnificent Seven technology stocks is negatively impacting the broader market [3][15][16] - Energy producers are experiencing gains, with WTI crude oil reaching a 2.5-month high [17] Federal Reserve Commentary - Minneapolis Fed President Neel Kashkari indicated that the US economy shows "resilience" and does not see the need for an interest rate cut this month [5] - Philadelphia Fed President Anna Paulson mentioned potential for modest rate adjustments later in the year if inflation moderates and growth stabilizes [6] International Trade - Better-than-expected trade news from China, with December exports rising by +6.6% year-over-year and imports increasing by +5.7% year-over-year, supporting global growth prospects [7] Earnings Season - Q4 earnings season is beginning, with S&P earnings growth expected to rise by +8.4%, and +4.6% excluding the Magnificent Seven technology stocks [10]

Economic Indicators - The US economy is showing "resilience" according to Minneapolis Fed President Neel Kashkari, who does not see the need for an interest rate cut this month [1] - US MBA mortgage applications increased by 28.5% in the week ending January 9, with purchase mortgage applications up 15.9% and refinancing applications up 40.1% [1] - US November retail sales rose by 0.6% month-over-month, exceeding expectations of 0.5% [2] - The Producer Price Index (PPI) for November increased by 3.0% year-over-year, also surpassing expectations of 2.7% [2] Stock Market Performance - The S&P 500 Index is down 0.75%, the Dow Jones Industrial Average is down 0.46%, and the Nasdaq 100 Index is down 1.22% [5] - Weakness in chip makers and the Magnificent Seven technology stocks is negatively impacting the broader market [4][16] - Energy producers are experiencing gains, with WTI crude oil reaching a 2.5-month high [17] Company-Specific News - Wells Fargo reported Q4 net interest income of $12.33 billion, below the consensus estimate of $12.43 billion, leading to a decline of more than 5% in its stock [19] - Trip.com ADRs fell over 15% following an investigation by Chinese regulators for alleged antitrust conduct [18] - TG Therapeutics shares rose over 9% after reporting preliminary full-year 2025 revenue of $616 million, exceeding the consensus of $606.1 million [20]

Market Overview - U.S. stock futures declined on Wednesday following a lower close on Tuesday, with major benchmark indices showing a downward trend [1] - The Consumer Price Index (CPI) rose 2.7% year over year in December, matching previous readings and economists' estimates, while core CPI was slightly below expectations at 2.6% [1] Economic Indicators - The 10-year Treasury bond yielded 4.17%, and the two-year bond yielded 3.52%, indicating investor sentiment towards interest rates [2] - The CME Group's FedWatch tool indicates a 97.2% likelihood of the Federal Reserve maintaining current interest rates in January [2] Stock Performance - Major indices showed the following performances: Dow Jones -0.15%, S&P 500 -0.16%, Nasdaq 100 -0.16%, Russell 2000 +0.14% [3] - SPDR S&P 500 ETF Trust (NYSE:SPY) was down 0.15% at $692.73, while Invesco QQQ Trust ETF (NASDAQ:QQQ) declined 0.20% to $625.00 in premarket trading [3] Company Focus - Wells Fargo & Co. (NYSE:WFC) was down 0.81% in premarket trading, with expected quarterly earnings of $1.67 per share on revenue of $21.65 billion [7] - BP PLC (NYSE:BP) dropped 1.84% after announcing potential writedowns of up to $5 billion in its energy transition businesses [7] - WeRide Inc. ADR (NASDAQ:WRD) rose 1.59% after launching the Robotaxi Mini Program "WeRide Go" on Tencent WeChat [7] Analyst Insights - Professor Jeremy Siegel anticipates a strong 2026 driven by productivity growth, with a surprising fourth-quarter GDP growth estimate of 5.4% [10] - Siegel suggests a shift in stock market leadership away from mega-cap technology stocks, predicting double-digit returns from small-cap stocks and non-tech cyclicals [11] Upcoming Economic Data - Delayed reports on U.S. retail sales and producer price index are scheduled for release at 8:30 a.m. ET [14] - Additional economic data, including business inventories and existing home sales, will be released at 10:00 a.m. ET [14] Commodities and Global Markets - Crude oil futures fell by 0.98% to around $60.57 per barrel, while gold prices rose by 0.93% to approximately $4,629.12 per ounce [16] - Bitcoin traded 3.32% higher at $94,969.36 per coin [16] Global Market Performance - Asian markets closed mixed, with India's Nifty 50 and China's CSI 300 indices falling, while Australia's ASX 200, Japan's Nikkei 225, Hong Kong's Hang Seng, and South Korea's Kospi indices rose [17]

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]

Core Insights - Roche's fenebrutinib demonstrated "unprecedented" test results for multiple sclerosis, impacting TG Therapeutics negatively [1][2] - Roche's stock increased by over 3% to $43.33, while TG Therapeutics' stock fell more than 5% to $30.53, reaching a two-month low [2] - Fenebrutinib showed significantly fewer relapses compared to teriflunomide in relapsing multiple sclerosis patients [3] - In primary progressive MS, fenebrutinib slowed disability progression comparably to Roche's Ocrevus, the only approved treatment for this condition [4] Roche's Competitive Position - Roche's fenebrutinib uses a different mechanism than TG Therapeutics' Briumvi, targeting BTK, which is involved in immune response to inflammation [7] - Roche's stock performance improved, gapping above its 50-day moving average following the news [7] TG Therapeutics' Market Performance - Briumvi's sales grew by at least double-digit percentages year-over-year, with a notable 84% increase to $152.9 million in Q3 [6] - Despite the sales growth, Briumvi still lags behind Ocrevus in overall sales [6] - TG Therapeutics maintains a strong IBD Digital Composite Rating of 97, ranking in the top 3% of stocks for performance [8]

Core Insights - TG Therapeutics reported adjusted earnings of $2.43 per share and $161.7 million in sales for Q3, significantly exceeding analyst expectations of $0.22 earnings per share and $152.1 million in sales [1][2] - The earnings beat was primarily attributed to a one-time tax benefit of $365 million, which, if excluded, would have resulted in earnings closer to $0.15 per share [2] - The company raised its full-year sales guidance to $600 million, with $585 million expected from U.S. sales of its multiple sclerosis drug Briumvi [3] Financial Performance - Q3 adjusted earnings: $2.43 per share [1] - Q3 sales: $161.7 million [1] - Analyst expectations: $0.22 earnings per share and $152.1 million in sales [2] - Previous year Q3 earnings: $0.02 per share and $83.9 million in sales [2] - Revised full-year sales guidance: $600 million [3] Market Reaction - TG Therapeutics stock increased by 4.4% to $36.30 in premarket trading [3] - Shares are trading slightly above their 50-day moving average [3] Ratings and Upgrades - TG Therapeutics received an upgrade in its IBD SmartSelect Composite Rating from 94 to 97 [4][7] - The company is now part of an elite list of stocks with a composite rating above 95 [7]

分组1 - Arcus Biosciences reported a quarterly loss of $1.27 per share, which was better than the Zacks Consensus Estimate of a loss of $1.33, and compared to a loss of $1 per share a year ago, indicating an earnings surprise of +4.51% [1] - The company posted revenues of $26 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 27.20%, although this was a decrease from year-ago revenues of $48 million [2] - Arcus Biosciences shares have increased approximately 24.9% since the beginning of the year, outperforming the S&P 500's gain of 16.9% [3] 分组2 - The earnings outlook for Arcus Biosciences is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Arcus Biosciences was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$1.24 on revenues of $20.06 million, and for the current fiscal year, it is -$3.70 on revenues of $228.48 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Arcus Biosciences belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - TG Therapeutics, another company in the same industry, is expected to report quarterly earnings of $0.24 per share, reflecting a significant year-over-year change of +1100%, with revenues projected to be $150.66 million, up 79.6% from the previous year [9]